- Home
- REX vs AKBA Comparison
REX vs AKBA Comparison
Compare REX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- AKBA
- Stock Information
- Founded
- REX 1980
- AKBA 2007
- Country
- REX United States
- AKBA United States
- Employees
- REX N/A
- AKBA N/A
- Industry
- REX Major Chemicals
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- AKBA Health Care
- Exchange
- REX Nasdaq
- AKBA Nasdaq
- Market Cap
- REX 847.7M
- AKBA 861.7M
- IPO Year
- REX N/A
- AKBA 2014
- Fundamental
- Price
- REX $62.77
- AKBA $3.11
- Analyst Decision
- REX Strong Buy
- AKBA Strong Buy
- Analyst Count
- REX 1
- AKBA 5
- Target Price
- REX $50.00
- AKBA $6.90
- AVG Volume (30 Days)
- REX 96.4K
- AKBA 4.2M
- Earning Date
- REX 08-27-2025
- AKBA 08-07-2025
- Dividend Yield
- REX N/A
- AKBA N/A
- EPS Growth
- REX N/A
- AKBA N/A
- EPS
- REX 2.98
- AKBA N/A
- Revenue
- REX $650,008,000.00
- AKBA $203,733,000.00
- Revenue This Year
- REX $3.27
- AKBA $38.23
- Revenue Next Year
- REX $17.11
- AKBA $38.17
- P/E Ratio
- REX $20.97
- AKBA N/A
- Revenue Growth
- REX N/A
- AKBA 16.75
- 52 Week Low
- REX $33.45
- AKBA $1.24
- 52 Week High
- REX $64.95
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- REX 75.25
- AKBA 41.92
- Support Level
- REX $59.64
- AKBA $2.98
- Resistance Level
- REX $64.95
- AKBA $3.32
- Average True Range (ATR)
- REX 1.78
- AKBA 0.13
- MACD
- REX 0.64
- AKBA 0.00
- Stochastic Oscillator
- REX 80.88
- AKBA 32.91
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.